221 related articles for article (PubMed ID: 37113732)
1. Development and validation of prognostic nomograms for large hepatocellular carcinoma after HAIC.
Yao W; Wei R; Jia J; Li W; Zuo M; Zhuo S; Shi G; Wu P; An C
Ther Adv Med Oncol; 2023; 15():17588359231163845. PubMed ID: 37113732
[TBL] [Abstract][Full Text] [Related]
2. Automatic prediction of hepatic arterial infusion chemotherapy response in advanced hepatocellular carcinoma with deep learning radiomic nomogram.
Xu Z; An C; Shi F; Ren H; Li Y; Chen S; Dou J; Wang Y; Yan S; Lu J; Chen H
Eur Radiol; 2023 Dec; 33(12):9038-9051. PubMed ID: 37498380
[TBL] [Abstract][Full Text] [Related]
3. Tyrosine kinase inhibitors, immune checkpoint inhibitors combined with hepatic arterial infusion of oxaliplatin and raltitrexed versus oxaliplatin, 5-fluorouracil and leucovorin for intermediate and advanced hepatocellular carcinoma: A retrospective study.
Zang M; Hu X; Yuan G; Li R; Li W; Pang H; Li Q; Chen J
Int Immunopharmacol; 2023 Dec; 125(Pt A):111019. PubMed ID: 37879230
[TBL] [Abstract][Full Text] [Related]
4. A Novel Nomogram for Predicting the Overall Survival in Patients with Unresectable HCC after TACE plus Hepatic Arterial Infusion Chemotherapy.
Liu B; Gao S; Guo J; Kou F; Liu S; Zhang X; Wang X; Cao G; Chen H; Liu P; Xu H; Gao Q; Yang R; Zhu X
Transl Oncol; 2023 Aug; 34():101705. PubMed ID: 37257332
[TBL] [Abstract][Full Text] [Related]
5. Survival benefit of preoperative hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin followed by hepatectomy for hepatocellular carcinoma.
Hu Z; Yang Z; Pan Y; Fu Y; Wang J; Zhou Z; Chen M; Hu D; Zhang Y
Front Pharmacol; 2023; 14():1210835. PubMed ID: 37456741
[No Abstract] [Full Text] [Related]
6. Prognostic nomogram predicting survival of patients with unresectable hepatocellular carcinoma after hepatic arterial infusion chemotherapy.
Mei J; Lin WP; Shi F; Wei W; Liang JB; Shi M; Zheng L; Li SH; Guo RP
Eur J Radiol; 2021 Sep; 142():109890. PubMed ID: 34375811
[TBL] [Abstract][Full Text] [Related]
7. A multitask deep learning radiomics model for predicting the macrotrabecular-massive subtype and prognosis of hepatocellular carcinoma after hepatic arterial infusion chemotherapy.
He X; Li K; Wei R; Zuo M; Yao W; Zheng Z; He X; Fu Y; Li C; An C; Liu W
Radiol Med; 2023 Dec; 128(12):1508-1520. PubMed ID: 37801197
[TBL] [Abstract][Full Text] [Related]
8. Hepatic arterial infusion chemotherapy and sequential ablation treatment in large hepatocellular carcinoma.
You H; Liu X; Guo J; Lin Y; Zhang Y; Li C
Int J Hyperthermia; 2022; 39(1):1097-1105. PubMed ID: 35993224
[TBL] [Abstract][Full Text] [Related]
9. Postprogression treatment of lenvatinib plus PD-1 inhibitor in advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy.
An C; Fu Y; Li W; Zuo M; Wu P
Cancer; 2023 Jul; 129(14):2235-2244. PubMed ID: 37029486
[TBL] [Abstract][Full Text] [Related]
10. Comparison Between Portal Vein Perfusion Chemotherapy and Neoadjuvant Hepatic Arterial Infusion Chemotherapy for Resectable Intermediate to Advanced Stage Hepatocellular Carcinoma.
Pan Y; Mei J; Chen J; Zhang D; Wang J; Wang X; Yi M; Zhou Z; Zhang Y; Chen M; Guo R; Xu L
Ann Surg Oncol; 2022 Mar; 29(3):2016-2029. PubMed ID: 34637058
[TBL] [Abstract][Full Text] [Related]
11. Prediction of therapeutic response of unresectable hepatocellular carcinoma to hepatic arterial infusion chemotherapy based on pretherapeutic MRI radiomics and Albumin-Bilirubin score.
Zhao Y; Huang F; Liu S; Jian L; Xia X; Lin H; Liu J
J Cancer Res Clin Oncol; 2023 Jul; 149(8):5181-5192. PubMed ID: 36369395
[TBL] [Abstract][Full Text] [Related]
12. OHCCPredictor: an online risk stratification model for predicting survival duration of older patients with hepatocellular carcinoma.
Tan J; Yu Y; Lin X; He Y; Jin W; Qian H; Li Y; Xu X; Zhao Y; Ning J; Zhang Z; Chen J; Wu X
Hepatol Int; 2024 Apr; 18(2):550-567. PubMed ID: 37067674
[TBL] [Abstract][Full Text] [Related]
13. Triple combination of HAIC-FO plus tyrosine kinase inhibitors and immune checkpoint inhibitors for advanced hepatocellular carcinoma: A systematic review and meta-analysis.
Tan Z; Zhang J; Xu L; Wang H; Mao X; Zou R; Wang Q; Han Z; Di Z; Wu D
PLoS One; 2023; 18(10):e0290644. PubMed ID: 37844117
[TBL] [Abstract][Full Text] [Related]
14. Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibodies with Hepatic Arterial Infusion Chemotherapy or Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma.
Yu B; Zhang N; Feng Y; Zhang Y; Zhang T; Wang L
J Hepatocell Carcinoma; 2023; 10():1735-1748. PubMed ID: 37822726
[TBL] [Abstract][Full Text] [Related]
15. Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis.
Fu Y; Peng W; Zhang W; Yang Z; Hu Z; Pang Y; Hu D; Chen J; Wang J; Zhou Z; Xu L; Chen M; Zhang Y
J Gastroenterol; 2023 Apr; 58(4):413-424. PubMed ID: 36894804
[TBL] [Abstract][Full Text] [Related]
16. Association of serum AFP trajectories and hepatocellular carcinoma outcomes after hepatic arterial infusion chemotherapy: A longitudinal, multicenter study.
An C; Wei R; Yao W; Han W; Li W; Shi G; Wu P
Cancer Med; 2024 Jun; 13(11):e7319. PubMed ID: 38819606
[TBL] [Abstract][Full Text] [Related]
17. Hepatic Arterial Infusion Chemotherapy with Modified FOLFOX as an Alternative Treatment Option in Advanced Hepatocellular Carcinoma Patients with Failed or Unsuitability for Transarterial Chemoembolization.
Hsu SJ; Xu X; Chen MP; Zhao ZY; Wang Y; Yin X; Zhang L; Ge NL; Chen Y; Wang YH; Luo JF; Ren ZG; Chen RX
Acad Radiol; 2021 Nov; 28 Suppl 1():S157-S166. PubMed ID: 33653656
[TBL] [Abstract][Full Text] [Related]
18. Hepatic arterial infusion chemotherapy versus transarterial chemoembolization for unresectable hepatocellular carcinoma: A systematic review with meta-analysis.
Si T; Huang Z; Khorsandi SE; Ma Y; Heaton N
Front Bioeng Biotechnol; 2022; 10():1010824. PubMed ID: 36237208
[No Abstract] [Full Text] [Related]
19. Hepatic arterial infusion chemotherapy and immune checkpoint inhibitors, alone or in combination, in advanced hepatocellular carcinoma with macrovascular invasion: a single-centre experience in Taiwan.
Wu JS; Hong TC; Wu HT; Lin YJ; Chang TT; Wang CT; Liu WC; Hsieh MT; Wu IC; Chen PJ; Chen CY; Lin SH; Chuang CH; Han MZ; Chen HP; Tsai HM; Kuo HY
J Gastrointest Oncol; 2023 Apr; 14(2):849-862. PubMed ID: 37201085
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness and prognostic model of hepatic arterial infusion chemotherapy for hepatocellular carcinoma with high tumor burden and/or Vp4 tumor thrombus compared with sorafenib: a post-hoc analysis of the FOHAIC-1 trial.
Chen QF; Lyu N; Wang X; Jiang XY; Hu Y; Chen S; Zhong SX; Huang ZL; Chen M; Zhao M
Int J Surg; 2023 Dec; 109(12):3929-3939. PubMed ID: 37678272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
